# Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in

> **NCT05198479** · PHASE2 · UNKNOWN · sponsor: **National Cancer Centre, Singapore** · enrollment: 25 (estimated)

## Conditions studied

- Metastatic Nasopharyngeal Cancer

## Interventions

- **RADIATION:** 77 Lu-DOTA0-Tyr3-Octreotate

## Key facts

- **NCT ID:** NCT05198479
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-05
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2023-10-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198479, "Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05198479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*